Introduction
The structure and function of AXL
The regulation of AXL gene expression
Gas6/AXL axis and its role in tumour development and progression
AXL promotes cell proliferation
AXL mediates migration and invasion
AXL affects epithelial-mesenchymal transition (EMT)
AXL in angiogenesis
AXL is associated with drug resistance in cancer treatment
AXL regulates the immune response
AXL is related to stem cell maintenance
AXL-targeted therapies
Small molecule inhibitors
Type I AXL inhibitors (Table 1)
Drug | Developer | Target(s)a | IC50 for AXL | Clinical Trial No.b | Phase of approval | Indications | Monotherapy/Combinations | Adverse events | Status |
---|---|---|---|---|---|---|---|---|---|
BGB324 (R428) | Rigel Pharmaceuticals/BerGen BIO | AXL (selective) | IC50 (in vitro) = 14 nM IC50 (in cells) = 14 nM | NCT02424617 | I/II | NSCLC | + Erlotinib | Not reported | Recruiting |
NCT03184558 | II | TNBC | + Pembrolizumab | Recruiting | |||||
NCT02488408 | Ib/II | AML, MDS | ± Cytarabine/decitabine | Recruiting | |||||
NCT02872259 | Ib/II | Metastatic melanoma | + Pembrolizumab; + Dabrafenib and trametinib | Recruiting | |||||
NCT03649321 | Ib/II | Pancreatic cancer | ± Nab-paclitaxel/gemcitabine/cisplatin | Recruiting | |||||
NCT03824080 | II | MDS | Monotherapy | Recruiting | |||||
TP-0903 | Tolero Pharmaceuticals | AXL (selective) | IC50 (in vitro) = 27 nM IC50 (in cells) = 222 nM | NCT03572634 | I/II | CLL | ± Ibrutinib | Not reported | Not yet recruiting |
NCT02729298 | I | Advanced solid tumors | Monotherapy | Recruiting | |||||
Crizotinib (PF-02341066, marketed as [Xalkori]) | Pfizer | MET, ALK, RON, AXL | IC50 (in vitro) = 294 nM IC50 (in vivo) = 322 nM | NCT02737501 | III | ALK-positive locally advanced or metastatic NSCLC | Crizotinib vs. Brigatinib | Abdominal pain, headache, pyrexia, pain in extremity, nausea | Active, not recruiting |
NCT02223819 | II | Uveal melanoma | Monotherapy | Active, not recruiting | |||||
NCT02435108 | II | MET-positive gastric cancer | Monotherapy | Completed | |||||
NCT02207504 | I | Castration-resistant prostate cancer | + Enzalutamide | Active, not recruiting | |||||
Bosutinib (SKI-606, Bosulif®) | Pfizer | ABL, SRC, AXL | IC50 (in vitro) = 174 nM | NCT02228382 | IV | Previously treated Ph + CML | Monotherapy | Diarrhea, rash, liver enzyme elevations | Active, not recruiting |
NCT03106779 | III | CML | Bosutinib vs. ABL001 | Recruiting | |||||
NCT01331291 | II | Glioblastoma | Monotherapy | Completed | |||||
NCT00319254 | II | Breast cancer | Monotherapy | Completed | |||||
NCT03023319 | I | Metastatic solid tumors | + Pemetrexed | Recruiting | |||||
Gilteritinib (ASP2215) | Astellas Pharma/Kotobuki Pharmaceutical | FLT3, AXL | IC50 (in vitro) = 0.73 nM | NCT02927262 | III | Relapsed or treatment refractory FLT3 mutated AML | Gilteritinib or placebo | Febrile neutropenia, anemia, thrombocytopenia, sepsis, pneumonia, diarrhea, fatigue, elevated aspartate aminotransferase and alanine aminotransferase | Recruiting |
NCT02456883 | I | Advanced solid tumors | Monotherapy | Completed | |||||
NCT02495233 | I/II | NSCLC | + Erlotinib | Terminated | |||||
S49076 | Servier | MET, MER, AXL FGFR3 | IC50 (in vitro) = 7 nM IC50 (in cells) = 56 nM | ISRCTN00759419 | I | Advanced solid tumors | Monotherapy | Peripheral oedema and hypoalbuminaemia | Completed |
Amuvatinib (MP-470) | Astex Pharmaceuticals | KIT, AXL, PDGFR1, FLT3, RET | IC50 (in vitro) = 10 nM | NCT01357395 | II | SCLC | Monotherapy | Fatigue, alopecia, diarrhea, nausea, anorexia, neutropenia, anemia, thrombocytopenia, leukopenia | Completed |
NCT00894894 | I | Solid tumors | Monotherapy | Completed | |||||
NCT00504205 | Not Applicable | Unresectable or metastatic solid tumor or lymphoma | Monotherapy | Terminated | |||||
Sunitinib (SU11248, marketed as Sutent) | Pfizer | PDGFR, VEGFR2, FLT3, KIT, AXL | IC50 (in vitro) = 5 nM | NCT00706706 | IV | Metastatic RCC | Monotherapy | Diarrhea, fatigue, hypertension, palmar-plantar erythrodysesthesia, and hematologic adverse events | Completed |
NCT02691793 | IV | Refractory Solid Tumors | Monotherapy | Recruiting | |||||
NCT01525550 | IV | Pancreatic neuroendocrine tumor | Monotherapy | Completed | |||||
NCT00793871 | IV | GIST | Monotherapy | Completed | |||||
NCT00794950 | II | Urothelial carcinoma | Monotherapy | Active, not recruiting | |||||
NCT01718327 | II | Unresectable and advanced cholangiocarcinoma | Monotherapy | Completed | |||||
NCT01824615 | II | Ovarian cancer | Monotherapy | Completed | |||||
NCT02623127 | II | Thymic carcinoma | Monotherapy | Completed | |||||
NCT00372775 | II | NSCLC | Monotherapy | Completed | |||||
NCT01498835 | I | Soft tissue sarcoma | Monotherapy | Completed | |||||
SNS314 2-D08 | Sunesis Pharmaceuticals | Aurora A/B/C, Trk A/B, FLT4, Fms, Axl | IC50 (in vitro) = 84 nM | NCT00519662 | I | advanced solid tumors | Monotherapy | Not reported | Completed |
AXL, IRAK4, ROS1 | IC50 (in vitro) = 0.49 nM | – | – | – | – | – | Preclinical | ||
UNC2025 | University of North Carolina | MER, FLT3, AXL, Tyro3 | IC50 (in vitro) = 14 nM | – | – | – | – | – | Preclinical |
SGI-7079 | Tolero Pharmaceuticals/Astex Pharmaceuticals | AXL (selective) | IC50 (in vitro) = 58 nM IC50 (in vivo) < 1 uM | – | – | – | – | – | Preclinical |
UNC569 | MER, AXL, Tyro3 | IC50 (in vitro) = 37 nM | – | – | – | – | – | Preclinical | |
NA80x1 | AXL (selective) | IC50 (in vitro) = 12.67 ± 0.45 μM, IC50 (in vivo) = 4.11 ± 1.47uM | – | – | – | – | – | Preclinical | |
DP-3975 | Deciphera Pharmaceuticals, LLC | AXL (selective) | IC50 (in vitro) = 100 nM ∼ 2 uM | – | – | – | – | – | Preclinical |
Type II AXL inhibitors (Table 2)
Drug | Developer | Target(s)a | IC50 for AXL | Clinical Trial No.b | Phase of approval | Indications | Monotherapy/Combinations | Adverse events | Status |
---|---|---|---|---|---|---|---|---|---|
Cabozantinib (Cabometyx, XL184, BMS-907351, marketed as Cometriq) | Exelixis/Ipsen company | VEGFR2, MET, RET, KIT, AXL, FLT1/3/4 | IC50 (in vitro) = 7 nM IC50 (in cells) = 42 nM | NCT01908426 | III | Advanced HCC | Monotherapy | Fatigue, diarrhea, hypertension, palmar-plantar erythrodysesthesia syndrome | Completed |
NCT01865747 | III | Advanced or metastatic RCC | Cabozantinib or Everolimus | Completed | |||||
NCT01716715 | II | Persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma | Cabozantinib vs. Paclitaxel | Completed | |||||
NCT00596648 | Ib/II | NSCLC | ± Erlotinib | Completed | |||||
BMS-777607 (ASLAN002) | Bristol-Myers Squibb/Aslan Pharmaceuticals | AXL, RON, MET, Tyro3 | IC50 (in vitro) = 1.1 nM | NCT00605618 | I/II | Advanced solid tumors | Monotherapy | Not reported | Completed |
NCT01721148 | I | Advanced solid tumors | Monotherapy | Completed | |||||
LY2801653 (Merestinib) | Eli Lilly and Company; Dana-Farber Cancer Institute | TEK, MET, AXL, RON | IC50 (in vitro) = 11 nM IC50 (in cells) = 2 nM | NCT02711553 | II | Advanced or metastatic biliary tract cancer | Ramucirumab or merestinib or placebo, + cisplatin and gemcitabine | Not reported | Active, not recruiting |
NCT02920996 | II | NSCLC | Monotherapy | Recruiting | |||||
NCT03027284 | I | Advanced and/or metastatic cancer | ± Other anti-cancer agents | Active, not recruiting | |||||
Foretinib (XL880, EXEL-2880, GSK1363089) | GSK | MET, VEGFR2, TIE-2, VEGFR3, RON, AXL | IC50 (in vitro) = 11 nM IC50 (in cells) < 100 nM | NCT01147484 | II | Recurrent breast cancer | Monotherapy | Fatigue, hypertension, gastrointestinal toxicities, nonfatal pulmonary emboli | Completed |
NCT00726323 | II | RCC | Monotherapy | Completed | |||||
NCT00920192 | I | HCC | Monotherapy | Completed | |||||
MGCD516 (Sitravatinib) | Mirati Therapeutics Inc. | DDR2, EPHA3, AXL, MER, VEGFR3 | IC50 (in vitro) = 1.5 nM IC50 (in cells) = 250–800 nM | NCT03680521 | II | Clear cell RCC | + Nivolumab | Not reported | Recruiting |
NCT02219711 | I/Ib | Advanced solid tumors | Monotherapy | Recruiting | |||||
MGCD265 (Glesatinib) | Mirati Therapeutics | MET, RON, VEGFR1/2/3, AXLc | Not reported | NCT02544633 | II | NSCLC with genetic alterations in MET | Monotherapy | Diarrhea, rash, fatigue | Completed |
NCT00697632 | I | Advanced malignancies | Monotherapy | Completed | |||||
NCT00975767 | I | NSCLC | + Erlotinib/docetaxel | Terminated | |||||
RXDX-106 (CEP-40783) | Ignyta, Inc. | AXL, MET, Tyro3, MER | IC50 (in vitro) = 7 nM | NCT03454243 | I | Advanced or metastatic solid tumors | Monotherapy | Not reported | Terminated |
Rebastinib (DCC-2036) | Deciphera Pharmaceuticals LLC | ABL, FLT3, VEGFR2, TIE-2, Lyn, SRC, FGR, AXL | IC50 (in vitro) = 42 nM | NCT03717415 | I/II | Locally advanced or metastatic solid tumor | + Carboplatin | Dry mouth, constipation, fatigue, muscular weakness, headache, nausea, blurred vision | Recruiting |
NCT00827138 | I | CML | Monotherapy | Completed | |||||
NPS-1034 | NeoPharm | AXL, MET | IC50 (in vitro) = 10.3 nM IC50 (in cells) < 0.5 μM | – | – | – | – | – | Preclinical |
LDC1267 | Lead Discovery Centre | MER, Tyro3, AXL | IC50 (in vitro) = 29 nM IC50 (in vivo) = ~ 15 μM | – | – | – | – | – | Preclinical |
Anti-AXL mAbs (Table 3)
Name | Type | Target | Indications | Phase of clinical trials |
---|---|---|---|---|
YW327.6S2 | Monoclonal antibody | AXL | NSCLC, breast cancer | Preclinical |
D9 | Monoclonal antibody | AXL | Pancreatic cancer | Preclinical |
E8 | Monoclonal antibody | AXL | Pancreatic cancer | Preclinical |
MAb173 | Monoclonal antibody | AXL | Kaposi sarcoma | Preclinical |
AXL-107-MMAE | Antibody-drug conjugate | AXL | Melanoma | Preclinical |
64Cu-anti-hAXL | 64Cu-labeled anti-human antibody | AXL | Breast cancer | Preclinical |
Axl specific CAR and SynNotch receptor | CAR and synNotch receptors | AXL | Leukemia | Preclinical |
GL21.T | RNA nucleotide aptamer | AXL | NSCLC | Preclinical |
GL21.T/miR-34c chimera | conjugate of miR-34c and GL21.T | AXL | NSCLC | Preclinical |
DNA AXL-APTAMER | DNA nucleotide aptamer | AXL | Ovarian cancer | Preclinical |